
Development of microbiome therapeutics to improve cancer treatment outcomes through immune modulation.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: December 2025
This analysis is not yet available in English. Please see the French version.
B
The organization is among the top 20% of organizations with the most committed CSR communication, excluding the top 5%, among comparable organizations.
Leading organizations
Innate Pharma
B
Development of cancer therapies using therapeutic antibodies that harness the immune system.
ipbs-toulouse (cnrs-ut3)
B
Research and development in cancer, infection, and inflammation to improve therapeutics.
Priothera
B
Development of innovative therapies for hematological malignancies, focusing on immune modulators to enhance outcomes in allogeneic hematopoietic cell transplantation and CAR T cell therapy.
Initiatives identified among leaders
Code de conduite
“Priothera développe des thérapies innovantes pour ...” - PriotheraSélection des membres du Conseil de surveillance en fonction de leur compétence et de leur diversité
“Innate Pharma sélectionne les membres de son Conse...” - Innate PharmaDevoir de protection des employés
“Priothera développe des thérapies innovantes pour ...” - Priothera33% of similar organizations communicate on CSR issues
+847 initiatives collected from 100 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports